A/HRC/7/30 page 10 Working Group is to promote innovation, research and development for neglected diseases, focusing on type II and type III diseases, and to promote access to all medicines. Emphasis was placed on the need for all stakeholders to work together to improve the delivery of all health products and medical devices, and effectively overcome the barriers to access. 23. The Government of Thailand was of the view that the scope of this report should include the importance of promoting innovation, research and development for neglected diseases, focusing on type II and III diseases; and promoting universal access to medication including diagnosis, care, treatment and access to medical devices and health products. The need for an innovative financing mechanism that is sustainable, transparent and accountable was also highlighted. It was also suggested that intellectual property rights should not be an impediment to access to medication, health-related research and technology transfer. Universal access requires an expansion and the effective implementation of existing mechanisms such as flexibilities provided in the TRIPS Agreement and the Doha Declaration. The application and management of intellectual property should be supported in a manner that maximizes health-related innovation, especially to meet the research and development needs of developing countries, and protects public health and access to health products for all. 24. The State of Qatar indicated an annual diagnosis of 300 active tuberculosis cases, 198 cases of malaria and 5 to 7 cases of HIV. Treatment for these diseases is available and easily accessible to all citizens and expatriates free of charge. The supply of antiretroviral medication is usually uninterrupted. Anti-tuberculosis treatment, both first-line and second-line, is available free of charge for all patients. Although Qatar does not have a malaria epidemic, anti-malaria drugs are readily available for inpatients and outpatients who require them. II. CONTRIBUTIONS FROM UNITED NATIONS BODIES A. Office of the United Nations High Commissioner for Human Rights 25. The Office of the United Nations High Commissioner for Human Rights (OHCHR) continues to address HIV/AIDS prevention, treatment, care and support as a human rights concern in the broader framework of the right to the highest attainable standard of physical and mental health. In collaboration with other United Nations agencies and programmes, the International Guidelines on HIV/AIDS and Human Rights are used both as an advocacy tool and to provide guidance on implementing a rights based response to the pandemic. The human rights treaty bodies and special procedures continue to draw attention to issues relating to access to HIV medications in concluding observations to State parties and in reports and communications made by special procedures. In his report to the General Assembly (A/61/338), the Special Rapporteur on the right to health noted that existing national and international policies, rules and institutions give rise to massive deprivations and inequalities in access to medicines. Combating HIV/AIDS, malaria and other diseases depends upon improving access to medicines. This includes making use of flexibilities in the TRIPS Agreement; developing and making available new drugs, vaccines and diagnostic tools for diseases in developing countries; and economic, financial and commercial incentives to influence research and development into specific health needs. In the view of the Special Rapporteur, access to medicines means medicines that are: accessible to all parts of the country; economically accessible; accessible without discrimination; and accompanied by accessible information about the medicines.